About Lynx biosciences, inc.

About company

LynxBiosciences(LynxBio)is a cytomics company focused on transforming the development of blood cancer therapies and delivering precise patient management by identifying the most promising therapeutic options. Many blood cancers are incurable; the standard of care is empirical treatment, typically through a trial and error process. Our initial focus is multiplemyeloma (MM) whereas patients ultimately relapse and undergo on average 5-7 treatments (ranging from $125,000 to $450,000 p.a.)